Crick — Clinical Intelligence Platform

Large-scale testing (Phase 3)Active Not RecruitingNCT04214067

What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Who this might be right for

Endometrial Endometrioid AdenocarcinomaStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

National Cancer Institute (NCI) 164

Results for “DMMR Cancer”

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer